Friday, February 07, 2025 11:14:43 PM
With AI Translated with Google The same page 5
The document outlines the scope of patients eligible for personalized vaccine studies and clinical trials, and details the implementation and public education strategies for oncological treatments in Brazil. Key points include:
• Patient Eligibility ( ??????? V-XIV): A range of patients with specific cancer types and conditions are listed as potential candidates for personalized vaccine studies, including those with non-small cell lung cancer, glioblastoma, and favorable biomarkers, among others.
• Implementation in SUS (Art. 8°): The implementation of these treatments within the Brazilian public health system (SUS) will be carried out through specific programs coordinated by the Ministry of Health, with support from state and municipal health secretariats.
• Public Education (Art. 9°): The Executive Branch will promote public education campaigns to raise awareness about the importance, benefits, and access to vaccines and oncological medications for cancer prevention and treatment.
Generative AI is experimental.
The document outlines the scope of patients eligible for personalized vaccine studies and clinical trials, and details the implementation and public education strategies for oncological treatments in Brazil. Key points include:
• Patient Eligibility ( ??????? V-XIV): A range of patients with specific cancer types and conditions are listed as potential candidates for personalized vaccine studies, including those with non-small cell lung cancer, glioblastoma, and favorable biomarkers, among others.
• Implementation in SUS (Art. 8°): The implementation of these treatments within the Brazilian public health system (SUS) will be carried out through specific programs coordinated by the Ministry of Health, with support from state and municipal health secretariats.
• Public Education (Art. 9°): The Executive Branch will promote public education campaigns to raise awareness about the importance, benefits, and access to vaccines and oncological medications for cancer prevention and treatment.
Generative AI is experimental.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
